Cortechs.ai | Cortechs.ai announces new capabilities for quantifying FLAIR lesions

Cortechs.ai announces new capabilities for quantifying FLAIR lesions

LesionQuant™, a NeuroQuant® product, enhances our current MRI volumetric image solution to include automated, fast and accurate FLAIR lesion segmentation and quantification.

(SAN DIEGO) Aug. 3, 2016 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce the release of LesionQuant LogoLesionQuant™ for FLAIR lesion identification, segmentation, and quantification. The addition of LesionQuant to the NeuroQuant® family of products marks a notable enhancement to NeuroQuant’s proven volumetric analysis capability by combining information from 2D or 3D FLAIR and 3D T1 MR images and providing lesion and brain structure quantification in a completely automated and optimized easy-to-read report.

Powered by Cortechs.ai’ NeuroQuant and Dynamic Atlas™ technology, LesionQuant delivers a comprehensive and trusted solution for consistent, quality-driven automated MR image analysis. LesionQuant is ready for clinical, research and clinical trial use, provides significant time savings over manual or semi-automatic lesion segmentation and quantification, and is available for a broad age range from 3 to 100 years. LesionQuant delivers further insight to clinicians by providing automated FLAIR lesion segmentation, quantification, and visualization.

“Cortechs.ai’ sole purpose is to enable superior clinical insight by advancing quantitative imaging to improve patient care,” said Guri Stark, Cortechs.ai’ CEO.  “The release of the LesionQuant product extension further solidifies NeuroQuant as the foremost solution in the evaluation of brain disorders. LesionQuant provides clinicians with objective, reliable and consistent quantitative information, aiding in their assessment of gray and white matter lesions, which can be found in a variety of neurological conditions, from Multiple Sclerosis to traumatic brain injury, as well as other neurological diseases.”

LesionQuant features and benefits:

  • Total number and volume of lesions
  • Lesion burden calculation
  • New and enlarging lesion identification and quantification
  • Color-coded lesion visualization
  • Color-coded lesion change visualization
  • Anatomical lesion distribution
  • Quantification of up to 8 relevant brain structures compared to our unique age- and gender-matched normative percentiles

LesionQuant licensing options are now available. For more information on LesionQuant, visit cortechs.ai/lesionquant.

About Cortechs.ai

Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

More Resources

04/10/2026

OnQ Prostate Vendor Validation: From Research to Clinical Adoption

OnQ Prostate delivers consistent, reliable AI-powered prostate MRI insights across vendors, ensuring confident diagnosis and streamlined clinical workflows.

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.
Scroll to Top